Trial · NCT02912260
Results by group120
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 120
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline To Week 12 In Hepatic Fat Fraction Assessed By Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) | MGL-3196 | -32.9 | Standard Error 3.0 | percent change | |
| Percent Change From Baseline To Week 12 In Hepatic Fat Fraction Assessed By Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) | Placebo | -10.4 | Standard Error 4.3 | percent change | |
| Percentage Of Participants With Adverse Events (AEs) | MGL-3196 | Week 12 | 71.4 | percentage of participants | |
| Percentage Of Participants With Adverse Events (AEs) | Placebo | Week 12 | 46.3 | percentage of participants | |
| Percentage Of Participants With Adverse Events (AEs) | MGL-3196 | Week 36 | 86.9 | percentage of participants | |
| Percentage Of Participants With Adverse Events (AEs) | Placebo | Week 36 | 68.3 | percentage of participants | |
| Percent Change From Baseline To Week 36 In Hepatic Fat Fraction Assessed By MRI-PDFF | MGL-3196 | -37.3 | Standard Error 3.7 | percent change | |
| Percent Change From Baseline To Week 36 In Hepatic Fat Fraction Assessed By MRI-PDFF | Placebo | -8.9 | Standard Error 5.4 | percent change | |
| Change From Baseline To Week 12 In Absolute Hepatic Fat Fraction Assessed By MRI-PDFF | MGL-3196 | -7.0 | Standard Error 0.6 | percentage | |
| Change From Baseline To Week 12 In Absolute Hepatic Fat Fraction Assessed By MRI-PDFF | Placebo | -2.7 | Standard Error 0.8 | percentage | |
| Change From Baseline To Week 36 In Absolute Hepatic Fat Fraction Assessed By MRI-PDFF | MGL-3196 | -8.2 | Standard Error 0.7 | percentage | |
| Change From Baseline To Week 36 In Absolute Hepatic Fat Fraction Assessed By MRI-PDFF | Placebo | -2.9 | Standard Error 1.0 | percentage | |
| Percentage Of Participants With At Least 30% Relative Fat Reduction at Week 12 | MGL-3196 | 60.3 | percentage of participants | ||
| Percentage Of Participants With At Least 30% Relative Fat Reduction at Week 12 | Placebo | 18.4 | percentage of participants | ||
| Percentage Of Participants With At Least 30% Relative Fat Reduction At Week 36 | MGL-3196 | 67.6 | percentage of participants | ||
| Percentage Of Participants With At Least 30% Relative Fat Reduction At Week 36 | Placebo | 29.4 | percentage of participants | ||
| Percentage Of Participants Achieving A 1-Point Reduction In Non-alcoholic Fatty Liver Disease Activity Score (NAS) At Week 36 | MGL-3196 | 76.7 | percentage of participants | ||
| Percentage Of Participants Achieving A 1-Point Reduction In Non-alcoholic Fatty Liver Disease Activity Score (NAS) At Week 36 | Placebo | 64.7 | percentage of participants | ||
| Percentage Of Participants Achieving A 2-Point Reduction In NAS At Week 36 | MGL-3196 | 56.2 | percentage of participants | ||
| Percentage Of Participants Achieving A 2-Point Reduction In NAS At Week 36 | Placebo | 32.4 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02912260/results